WORLD PEPTIDEFOUNDATION

Peptide directory

Find a peptide

Public profiles inside a larger governed registry

Search by peptide name, brand, or research code. Open a full evidence profile or the published sources available for a record still in development. Source publication does not mean a completed scientific appraisal.

Browse the Master RegistryExplore research atlasesFind studies worldwide

The registry is an expanding catalog, not a complete list of every peptide. A missing public result does not mean no research exists.

Published profiles

Search profiles and sources

Compare peptides side by side →
Refine by category
Category

405 peptide records

  • PTHrP analog

    Abaloparatide

    Peptide analog

    Emerging

    Abaloparatide is a synthetic 34-residue analog of human parathyroid hormone-related protein, PTHrP(1–34), designed to activate the parathyroid hormone type 1 receptor. Intermittent subcutaneous exposure produces an osteoanabolic response by stimulating osteoblast activity and increasing bone formation. The molecule contains an α-aminoisobutyric-acid substitution and is distinct from endogenous PTHrP and from teriparatide. Regulatory authorization is product- and jurisdiction-specific: the FDA-approved TYMLOS label covers defined high-fracture-risk postmenopausal women and men, while the EMA-authorized ELADYNOS indication is for postmenopausal women at increased fracture risk.

    Evidence and record details

    Evidence integrity map

    Human 1Preclinical 0Durable IDs 6Open signals 2
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    4 open research questions
    Evidence review date
    Documented human review recorded Sep 20, 2026

    Source verification checks records; it does not itself approve scientific conclusions.

    View evidence profile for Abaloparatide

  • Amylin receptor research peptide

    AC187

    Published sources available; full evidence profile in development.

    3 published source records. Source publication does not imply scientific appraisal.

    Open sources for AC187 →

  • ACTH peptide fragment

    ACTH(1-17)

    Published sources available; full evidence profile in development.

    3 published source records. Source publication does not imply scientific appraisal.

    Open sources for ACTH(1-17) →

  • ACTH peptide fragment

    ACTH(4-10)

    Published sources available; full evidence profile in development.

    2 published source records. Source publication does not imply scientific appraisal.

    Open sources for ACTH(4-10) →

  • Endogenous growth factor protein

    Activin A

    Published sources available; full evidence profile in development.

    2 published source records. Source publication does not imply scientific appraisal.

    Open sources for Activin A →

  • Endogenous peptide

    Adropin

    Published sources available; full evidence profile in development.

    1 published source records. Source publication does not imply scientific appraisal.

    Open sources for Adropin →

  • Melanocortin peptide analog

    Afamelanotide

    Peptide analog

    Emerging

    Afamelanotide is a melanocortin peptide analog. The research record considers pigmentation biology and clinical outcomes in erythropoietic protoporphyria, alongside distinct exploratory questions such as UV responses and vitiligo. These settings should be kept separate.

    Evidence and record details

    Evidence integrity map

    Human 0Preclinical 0Durable IDs 5Open signals 2
    Publication state
    Published profile
    Verified source records
    45 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    No open questions documented
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

    View evidence profile for Afamelanotide

  • Endogenous vasoactive peptide

    Alamandine

    Published sources available; full evidence profile in development.

    2 published source records. Source publication does not imply scientific appraisal.

    Open sources for Alamandine →

  • GLP-1 analog fusion protein

    Albiglutide

    Published sources available; full evidence profile in development.

    4 published source records. Source publication does not imply scientific appraisal.

    Open sources for Albiglutide →

  • Growth hormone secretagogue peptide

    Alexamorelin

    Published sources available; full evidence profile in development.

    1 published source records. Source publication does not imply scientific appraisal.

    Open sources for Alexamorelin →

  • Endogenous neuropeptide

    Alpha-CGRP

    Published sources available; full evidence profile in development.

    3 published source records. Source publication does not imply scientific appraisal.

    Open sources for Alpha-CGRP →
How the public directory relates to the 500-record Master Registry

master registry transparency

500 master records, with governance status shown explicitly

WPF-MASTER-REGISTRY-TRANSPARENCY-1.0
501
Master records
467
Governed records
34
Review-deferred
458
Peptide acquisition eligible
9
Governed comparators

The master registry has 467 governed identities from 501 records. 34 remain review-gated. Nine governed records are scientific comparators, leaving 458 peptide identities in the source acquisition cohort. Database reconciliation is a separate step. The 51 profiles shown on this directory are a represented public-profile subset, not the size of the master registry. All 51 public profiles on this render reconcile to governed peptide identities in that registry; unknown, duplicate, deferred, or comparator identities fail closed instead of appearing publicly.

Explore the full Master Registry →
What the profile status labels mean

Evidence, chemistry, and regulatory counts include only records that crossed the relevant public-publication gate. A zero means none published in that lane—not that nothing is known. “No governed record published” is a publication-state disclosure; internal or pending material may exist without appearing in public counts. Source verification, editorial publication, and accountable scientific appraisal are distinct states; a source count alone does not approve a scientific conclusion.

Recently updated public records

When each public profile record was last changed — not clinical or scientific activity.